Eye infections are common and represent a major healthcare burden.
persisted, her vision declined in association with increased photophobia and on day 11 she was referred to our cornea service. In the temporal mid-peripheral stroma were two inactive nummular opacities. There was no evidence of radial keratoneuritis.
Central corneal sensation by Cochet Bonnet aesthesiometry was 1.0 mm OD and 25-30 mm OS (normal ~45+mm). Schirmers with anesthesia were 6.0 mm OD and 3.0 mm OS. Pain levels were reported as mild, never exceeding 2/10 from infection onset.
A multifactorial diagnosis was established including trifluridine toxicity OD, neurotrophic keratitis OD, active immune stromal keratitis OD, inactive infectious herpes simplex keratitis OD, aqueous deficient dry eye OU, corneal hypoesthesia OS and amblyopia OS. The trifluridine was discontinued and prednisolone reduced to BID.
At six days post trifluridine discontinuation, the corneal findings remained unchanged prompting silicone punctual plug insertion at the right lower lid, followed by a collagen plug at the right upper lid on day 10. Three days later, the diffuse keratopathy field had resolved, but the central dentritiform lesion remained. By post trifluridine day 19, the dendritiform lesion had had noticeably receded and the vision had improved to 20/80.
Throughout all of her visits to this point, the patient had expressed a highly emotional, frequently tearful, fear of blindness. On post trifluridine day 31, she was hospitalized secondary to a massive cerebrovascular accident (CVA) with associated hemi-paresis and dysphasia. She was not seen in our clinic again until post trifluridine Ganciclovir in the Treatment of Ophthalmic Viral Infections -Case Reports 
Case 2
A 58-year-old caucasian female presented to her primary eye care provider complaining of a seven-day history of increasing lid swelling, redness, tearing, and foreign body sensation OS. Her past ocular history was significant only for LASIK OU performed seven years prior. The patient expressed his concern regarding contagiousness to his children. After explaining its off-label use, he was started on ganciclovir gel 5x daily on the left eye. He was asked to continue use of steroid drops once a day. The cultures were negative for viral growth. He followed up after one week with much-improved signs and symptoms.
Case 5
A 59-year-old male presented with a one-day history of eye pain and redness in both eyes. This was associated with watery eye discharge, swelling, and slightly blurred vision. Examination of the both eyes showed visual acuities of 20/30, with conjunctival injection and follicular changes on the upper and lower palpebral conjunctivae. He had several subepithelial coarse infiltrates in both corneas. Swabs from both eyes were sent for viral culture. The clinical findings were suggestive of bilateral EKC and he was prescribed ganciclovir to be used 5x daily in both eyes. He was followed up after four days.
Patient reported slight improvement of symptoms. There was no change in both conjuctival and corneal signs. Cultures were positive for adenovirus. The patient was asked to continue using ganciclovir gel and add steroid eye drops. On his next visit a week later, the patient reported complete resolution of his symptoms. Although conjunctival injection and follicles were still present, they resolved a week later.
He had some residual SEIs, which were not affecting the visual axis.
The patient refused to use steroids and was maintained on artificial tear drops.
Discussion
The first case of the series is a complex and ultimately tragic one that offers a poignant reminder of the risks of trifluridine toxicity, the extended timeframe potentially required for its reversal, and the unpredictable morbidities associated with that process. The pre-existing aqueous deficient dry eye, neurotrophic disease and post infectious inflammation, coupled with exposure to multiple preservative-containing medications including the highly toxic thimerosal-containing trifluridine predisposed this patient to severe and extended ocular surface disturbance. It is not difficult to invoke the stress of this preservative-related complication as an important etiologic element to this patient's otherwise non-predisposed massive and tragic CVA.
Although adenoviral EKC can clinically manifest in a highly asymmetric fashion and the latter four patients represent only a few anecdotal cases, they nevertheless raise intriguing possibilities regarding the potential application of ganciclovir for the treatment of at least some serotypes of adenoviral conjunctivitis.
In particular for Case 2, not only did ganciclovir appear to benefit this patient, but it seemed to clinically 'freeze' disease progression at the point of application. The left eye, one full week into symptomatic infection and demonstrating a highly virulent viral strain, began improving just two days after ganciclovir introduction. The right eye, treated just 24 hours into symptom manifestation, never progressed beyond moderate conjunctival injection.
Finally, the three weeks of lost working time suffered by this patient, not to mention the infection's possible spread to family, friends and coworkers, highlight the potential magnitude of personal, professional and economic morbidity associated with adenoviral conjunctivitis. It also emphasizes the value of an effective therapeutic intervention which to this point has not been available. Currently, there is no approved treatment for adenoviral conjunctivitis and management is usually symptomatic and supportive. 9 Recently, antivirals such as cidofovir (Vistide ® ) have been shown to be effective against some adenoviral serotypes; however, clinical use has been limited due to their toxicities. 10, 11 Ganciclovir is clinically effective and approved against herpesvirus infections when applied topically onto the eye. 12 Its mechanism of action involves inhibiting viral DNA replication through direct incorporation into viral DNA following its phosphorylation by viral thymidine kinase. This results in eventual termination of viral DNA elongation. 12, 13 It also makes the drug specific for infected cells and thus less toxic to non-affected cells.
In 1997, Chen and colleagues gave the first report on the use of systemic ganciclovir against adenovirus. 14 They described a case of a 47-year-old patient who was successfully treated for culture positive adenoviral
In adenoviral keratoconjunctivitis, it has been suggested that ganciclovir can help achieve faster resolution of signs and symptoms, 5, 18 reduce contagiousness of the disease 5 and prevent subepithelial opacities. 18 
